louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05871710: Validity and Reliability of the Turkish Version of the Tele-Pulmonary Rehabilitation Acceptance Scale
Official title: Validity and Reliability of the Turkish Version of the Tele-Pulmonary Rehabilitation Acceptance Scale
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Pulmonary Disease
Telehealth
Pulmonary Rehabilitation
Lead sponsor: Uskudar State Hospital
Sponsor class: OTHER_GOV
First posted: 2023-05-23
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Native Turkish-speaking patients in need of pulmonary rehabilitation and native Turkish-speaking healthcare professionals working in the field of pulmonary rehabilitation.

Brief summary: The objective of this research is to translate the Tele-Pulmonary Rehabilitation Acceptance Scale into Turkish and assess its reliability and accuracy.

Detailed description: The use of telehealth in pulmonary rehabilitation, also known as telerehabilitation, is a novel approach in healthcare practice. In order to effectively implement telerehabilitation programs, it is important to evaluate how potential users perceive and accept this new type of program. Thus, the aim of this research was to create a measuring tool that could assess the level of acceptance of telerehabilitation among healthcare providers and patients. A group of experts in pulmonary rehabilitation, telehealth, information technology, and scale development have reviewed and confirmed the content validity of the Tele-Pulmonary Rehabilitation Acceptance Scale. This scale is significant because it offers a consistent means of collecting data to measure the level of acceptance towards telerehabilitation among potential users. This study aims to translate and show the consistency and validity of the Tele-Pulmonary Rehabilitation Acceptance Scale in Turkish.

Eligibility criteria: Inclusion Criteria:

* Being a patient in need of pulmonary rehabilitation or a healthcare professional working in the field of pulmonary rehabilitation.
* Being a native Turkish speaker.
* Giving consent to participate in the study.

Exclusion Criteria:

* Any disease or condition that prevents reading, understanding, or filling out forms.
* Not giving consent to participate in the study.

Primary outcomes:
measure: Validity and reliability of the Turkish version of the Tele-Pulmonary Rehabilitation Acceptance Scale
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Uskudar State Hospital
name: Mustafa H Temel, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01133210: Effect of Maraviroc on Metabolic Function in Obese Subjects (Phase I)
Official title: Effect of Maraviroc on Metabolic Function in Obese Subjects (Phase I)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Hypertriglyceridemia
Keywords: hypertriglyceridemia
triglyceride
cholesterol
Maraviroc
Lead sponsor: Washington University School of Medicine
Sponsor class: OTHER
Collaborators: name: Pfizer
First posted: 2010-05-28
Enrollment: 27
Sex: ALL
Minimum age (years): 18
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the effect of maraviroc therapy in obese insulin resistant subjects on:

1. Plasma triglyceride concentration
2. Plasma HDL-cholesterol and LDL-cholesterol concentrations
3. Plasma markers of cardiometabolic risk and inflammation

Detailed description: The purpose of this study is to determine, in obese insulin resistant subjects, the effect of maraviroc therapy, a selective antagonist of the human chemokine receptor CCR5, on:

1. Plasma triglyceride concentration
2. Plasma HDL-cholesterol and LDL-cholesterol concentrations
3. Plasma markers of cardiometabolic risk and inflammation

Eligibility criteria: Inclusion Criteria:

* obese (body mass index (BMI) between 30 and 45.9)
* increased plasma triglyceride concentrations (150-400 mg/dL)

Exclusion Criteria:

* active or previous infection with hepatitis B or C
* history of alcohol abuse
* current alcohol consumption (\>20g/day)
* severe hypertriglyceridemia (\>400 mg/dL)
* active peptic ulcer disease
* diabetes
* pregnant or lactating
* take statins, fibrates, niacin, moderate to strong Cyp3A4 inhibitors or inducers, or any other medication that might confound interpretation of the study results will be excluded.

Primary outcomes:
measure: effect of Maraviroc on plasma triglyceride concentration
timeFrame: 12 weeks
Secondary outcomes:
measure: Effect of Maraviroc on serum HDL concentration
timeFrame: 12 weeks
measure: effect of Maraviroc on serum LDL-cholesterol concentration
timeFrame: 12 weeks
measure: Effect of Maraviroc on plasma markers of cardiometabolic risk and inflammation
timeFrame: 12 weeks
Other outcomes:
Locations:
city: St. Louis
country: United States
facility: Washington University School of Medicine
state: Missouri
Study officials:
affiliation: Washington University School of Medicine
name: Samuel Klein, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00749710: Blood Loss and Complications of Internal Fixation of Femoral Neck Fractures in Patients Treated With Clopidogrel
Official title: Blood Loss and Complications of Internal Fixation of Femoral Neck Fractures in Patients Treated With Clopidogrel
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Femoral Neck Fractures
Pertrochanteric Fractures
Antiaggregant Therapy
Keywords: femoral neck fractures
pertrochanteric fractures
antiaggregant therapy
clopidogrel
plavix
Lead sponsor: Tel-Aviv Sourasky Medical Center
Sponsor class: OTHER_GOV
First posted: 2008-09-09
Enrollment: 100
Sex: ALL
Minimum age (years): 60
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Patients suffering from femoral neck or pertrochanteric fractures have a high rate of mortality and morbidity associated mainly with deconditioning and immobilization. Surgical management including open reduction and internaql fixation has been shown to reduce complication and improve outcome in such patients. Delay of surgery produces less optimal results and is associated with higher morbidity even after 24-48 hours of fracture event.

Patients treated with platelet antiaggregants are exposed to higher blood loss during surgery and related complications, as demonstrated in patients treated with Aspirin. However, cessation of antiaggregant therapy before surgery may be associated with complications of a hypercoagulable state and surgery delay.

Clpopidogrel is a fairly new approved antiaggregant drug indicated in cases of failed aspirin treatment in ischemic heart disease and cerebrovascular disease patients as well as in primary prevention of stent restenosis.

No data regarding complications of hip surgery in patients treated with Clpopidogrel is available.

Study hypothesis:

Definitive surgical treatment of patients treated with clopidogrel undergoing open reduction and internal fixation of pertrochnteric and femoral neck fractures is safe although associated with more extensive blood loss during surgery and postoperative wound complications.


Eligibility criteria: Inclusion Criteria:

* age \> 60
* pertrochanteric or femoral neck fracture within 48 hours
* clopidogrel treatment - study group
* no antiaggregant treatment - control group
* ASA score \<=3

Exclusion Criteria:

* hematologic malignancy
* hematologic malfunction
* warfarin treatment
* previous active GI or other internal bleeding - within 1 year
* thrombocytopenia \< 150

Primary outcomes:
measure: mortality 30 days, 1 year functional score 1 year blood loss at surgery blood transfusions during hospitalization wound complications
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Tel-Aviv Sourasky Medical Center
name: Ely Steinberg, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Wehren LE, Magaziner J. Hip fracture: risk factors and outcomes. Curr Osteoporos Rep. 2003 Sep;1(2):78-85. doi: 10.1007/s11914-003-0013-8.
Clinical trial NCT06762210: The Effectiveness of AI Molar Mind for Smoking Cessation Through Dental Health Evaluation
Official title: The Effectiveness of AI Molar Mind for Smoking Cessation Through Dental Health Evaluation: Randomized Control Trial
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Smoking Cessation; Tobacco Dependence
Keywords: Smoking cessation
oral health
Lead sponsor: Fayoum University
Sponsor class: OTHER
First posted: 2025-01-07
Enrollment: 300
Sex: ALL
Minimum age (years): 21
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: A randomized, controlled, single-blind clinical trial with two parallel arms.
Primary purpose: SUPPORTIVE_CARE

Brief summary: Smoking cessation remains a significant public health challenge, with millions of individuals struggling to quit despite available interventions.

Detailed description: Oral health deterioration is a well-documented consequence of smoking, including periodontal disease, tooth discoloration, and oral cancer. Recent advancements in artificial intelligence (AI) have led to the development of AI Molar Mind, a digital tool designed to assess oral health and provide personalized feedback to motivate behavioral change. This study aims to evaluate the efficacy of AI Molar Mind in aiding smoking cessation by leveraging oral health evaluations as a motivational tool.

Eligibility criteria: Inclusion Criteria:

* Adults aged 18-65 years
* smoke ≥5 cigarettes per day
* motivated to quit smoking,
* have access to a smartphone or computer

Exclusion Criteria:

* Pregnant women
* individuals with severe psychiatric conditions
* those already using other smoking cessation therapies.

Primary outcomes:
measure: smoking cessation indicator
timeFrame: base line, 6-month post smoking cessation
Secondary outcomes:
Other outcomes:
Locations:
city: Fayoum
country: Egypt
facility: faculty of Dentistry, Fayoum University
state: Alexandria
Study officials:
affiliation: Fayoum University
name: Alshaimaa Mohamed, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Oya-Watanabe Y, Inagaki K, Nimi T, Yamamoto Y, Tanabe T, Okai M, Segawa N, Watanabe T, Uchibori N, Koide T, Inukai J, Yuasa H, Mitani A, Nagao T, Fukui M, Hinode D. Attitudes toward smoking cessation according to smoking status among dentists in the Aichi Dental Association in Japan. Tob Induc Dis. 2024 Aug 6;22. doi: 10.18332/tid/191290. eCollection 2024.
citation: Herpich TL, Mendes EM, Roxo-Goncalves M, Katz N, Almeida JD, Martins MD, Romanini J, Carrard VC. Impact of an educational intervention regarding tobacco counseling on dentists and dental students. Braz Oral Res. 2024 Nov 8;38:e102. doi: 10.1590/1807-3107bor-2024.vol38.0102. eCollection 2024.
Clinical trial NCT06932510: EFFECTS OF INFLATTABLE CERVICAL TRACTION COLLAR AS COMPARED TO MANUAL TRACION IN THE MANAGEMENT OF CERVICAL RADICULOPATHY
Official title: EFFECTS OF INFLATTABLE CERVICAL TRACTION COLLAR AS COMPARED TO MANUAL TRACION IN THE MANAGEMENT OF CERVICAL RADICULOPATHY
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: NA
Conditions: Cervical Radiculopathy
Lead sponsor: Foundation University Islamabad
Sponsor class: OTHER
First posted: 2025-04-17
Enrollment: 40
Sex: ALL
Minimum age (years): 19
Maximum age (years): 44
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is a randomized control trial and the purpose of this study is to determine the effects of inflatable cervical traction collar as compared to manual traction in the management of cervical radiculopathy.

Detailed description: The purpose of this study is to determine the effects of inflatable cervical traction collar as compared to manual traction in the management of cervical radiculopathy on

1. Pain
2. Functional Disability
3. Range of motion Data collection procedure: Participants of interest would be approached and explained about the research. Informed written consent will be taken. Recruited participants will be allocated to either of the groups through a sealed opaque envelope method.

Eligibility criteria: Inclusion Criteria:

Adults aged 19-44 years Neck pain \>4 and \<8 on NPRS NDI scoring \<24(moderate disability) Positive Spurling test Positive Distraction Test Active and passive ROM limited/painful towards the side of pain Radiating Symptoms Numbness/paresthesia radiating to upper limb Both genders Positive - Upper Limb Neural Tension Tests (ULNTT) will be included. -

Exclusion Criteria:

Patients having Bilateral radiating sign and symptoms Cervical myelopathy Cervical syringomyelia Rheumatoid arthritis Thoracic outlet syndrome Brachial plexopathy Cervical Rib Vertebrobasilar insufficiency Recent history of fracture, surgery, trauma or whiplash Positive alar ligament stress test Positive sharp purser stress test Cervical instability Cancer, tumor or sudden weight loss.

-

Primary outcomes:
measure: Neck Pain
timeFrame: 2 weeks
measure: Neck Disability Index
timeFrame: 2 weeks
measure: Cervical Range of Motion
timeFrame: 2 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Islamabad
country: Pakistan
facility: Foundation University College of Physical Therapy, Foundation University Islamabad.
Study officials:
affiliation: Foundation University Islamabad
name: Mehwish Iqbal, DPT
role: PRINCIPAL_INVESTIGATOR
affiliation: Foundation University Islamabad
name: Muhammad Osama, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT06122610: Using Novel Imaging to More Safely Treat Neuroendocrine Tumors
Official title: Dosimetry-Guided 177Lu-DOTATATE Treatment Planning Using 64Cu-DOTATATE as a Surrogate
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Neuroendocrine Tumors
Somatostatin Receptor-positive Neuroendocrine Tumor
Keywords: neuroendocrine tumors
Lead sponsor: University of Wisconsin, Madison
Sponsor class: OTHER
First posted: 2023-11-08
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The goal of this research is to determine if DetectnetTM PET/CT can be used to make Lutathera therapy safer for patients with neuroendocrine cancer.

Participants will:

* Complete two phases involving 6 visits
* Undergo additional research PET/CT, and possibly SPECT/CT scans

Detailed description: The goal of this research study is to determine if DetectnetTM PET/CT scanning over several days can be used to deliver Lutathera in a safer manner.

In this research, participants will be asked to complete a screening phase and possibly a dosimetry phase. The screening phase will require 2 visits. The dosimetry phase will also require 3 research visits.

Eligibility criteria: Inclusion Criteria:

* Candidates for 177Lu-DOTATATE (Lutathera) treatment for somatostatin receptor-positive neuroendocrine tumor

Exclusion Criteria:

* Unable to lie flat during or tolerate PET/CT or SPECT/CT
* Known incompatibility to CT. SPECT, or PET scans
* Unlikely to comply with study procedures, restrictions and requirements and judged by the investigator that the participant is not suitable for participation in the study

Primary outcomes:
measure: Compare pre-therapy and post-therapy voxel-based dosimetry estimates
timeFrame: Baseline and 120 hours post-dose
Secondary outcomes:
measure: Absorbed radiation doses
timeFrame: 1 hour post-dose, 4 hours post-dose, 48 hours post-dose, 120 hours post-dose
measure: Absorbed radiation doses of 64Cu-DOTATATE
timeFrame: 1 hour post-dose, 4 hours post-dose, 48 hours post-dose, 120 hours post-dose
measure: Compare 3D voxel-based versus model based dosimetry in participants receiving 177Lu_DOTATATE
timeFrame: Baseline and 120 hours post-dose
Other outcomes:
Locations:
city: Madison
country: United States
facility: University of Wisconsin - Madison
state: Wisconsin
Study officials:
affiliation: University of Wisconsin, Madison
name: Steve Cho, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01242410: Prevention of Preterm Birth Using Cervical Pessary in Pregnant Women With Short Cervix in Twins
Official title: Randomized Controlled Trial: Prevention of Preterm Birth Using Cervical Pessary in Pregnant Women With Short Cervix in Twins
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Preterm Birth
Keywords: Short cervix
Preterm birth
Cervical pessary
Twins
Lead sponsor: Maternal-Infantil Vall d´Hebron Hospital
Sponsor class: OTHER
First posted: 2010-11-17
Enrollment: 137
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Placement of a vaginal pessary reduces significantly the rate of spontaneous preterm birth in pregnant women with twins and a short cervical length at 18-22 weeks scan.

Detailed description: This trial includes pregnant women with twins undergoing routine ultrasound examination at 18.0 to 22.6 weeks of gestation.

Eligibility criteria: Inclusion Criteria:

* Twins
* Minimal age of 18 years

Exclusion Criteria:

* Major fetal abnormalities (requiring surgery or leading to infant death or severe handicap)
* Spontaneous rupture of membranes at the time of randomization
* Cervical cerclage in situ
* Active vaginal bleeding
* Placenta previa

Primary outcomes:
measure: Spontaneous delivery before 34 completed weeks
timeFrame: Each 6 months
Secondary outcomes:
measure: Birth weight
timeFrame: Each 6 months
measure: Fetal-Neonatal Death
timeFrame: Each 6 months
measure: Neonatal morbidity
timeFrame: Each 6 months
measure: Maternal adverse effects
timeFrame: Each 6 months
measure: Preterm birth before 37 weeks or 28 weeks
timeFrame: Each 6 months
measure: Rupture of membranes before 34 weeks
timeFrame: Each 6 months
measure: Hospitalisation for threatened preterm labour
timeFrame: Each 6 months
Other outcomes:
Locations:
city: Barcelona
country: Spain
facility: Hospital Vall d'Herbron
Study officials:
affiliation: Hospital Vall d'Hebron
name: Elena Carreras
role: STUDY_DIRECTOR
affiliation: Hospital Vall d'Hebron
name: Maria M Goya
role: PRINCIPAL_INVESTIGATOR
References:
citation: Goya M, de la Calle M, Pratcorona L, Merced C, Rodo C, Munoz B, Juan M, Serrano A, Llurba E, Higueras T, Carreras E, Cabero L; PECEP-Twins Trial Group. Cervical pessary to prevent preterm birth in women with twin gestation and sonographic short cervix: a multicenter randomized controlled trial (PECEP-Twins). Am J Obstet Gynecol. 2016 Feb;214(2):145-152. doi: 10.1016/j.ajog.2015.11.012. Epub 2015 Nov 25.
Clinical trial NCT02997410: Ozone Therapy for Masticatory Muscle Pain (OTMMP)
Official title: Effect of High-frequency Bio-oxidative Ozone Therapy for Masticatory Muscle Pain: a Double-blind Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Orofacial Pain
Temporomandibular Joint Disorders
Keywords: Ozone
Lead sponsor: Istanbul University
Sponsor class: OTHER
First posted: 2016-12-20
Enrollment: 60
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study investigates the efficacy of bio-oxidative ozone application in the treatment of TMD of muscular origin.

Detailed description: Ozone is a natural pale blue gas that can be found in the atmosphere. Medical grade ozone is a powerful oxidizing agent which can be produced commercially in ozone generators. Ozone can have effects on blood components and positively affect oxygen metabolism, cell energy, immunomodulation and microcirculation.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of myofascial pain according to the Research Diagnostic Criteria for Temporomandibular Disorder (RDC/TMD)
* Natural posterior occlusion.

Exclusion Criteria:

* Any TMJ internal derangement
* Inflammatory connective tissue disease
* Psychiatric problem
* Tumour
* Hearth disease or pacemaker
* Pregnancy
* Other orofacial region disease symptoms (e.g. toothache, neuralgia, migraine)
* Treatment or medication use for headache or bruxism in the last 2 years
* Local skin infection over the masseter or temporal muscle

Primary outcomes:
measure: Change From Baseline in Pain Values (kg/cm2) on the Pressure pain threshold measurement (PPT) using a Pressure Algometry at 1 month
timeFrame: Change from Baseline Pain Values (kg/cm2) at 1 month
measure: Change From Baseline in Pain Values (kg/cm2) on the Pressure pain threshold measurement (PPT) using a Pressure Algometry at 3 months
timeFrame: Change from Baseline Pain Values (kg/cm2) at 3 months
measure: Change From Baseline in Pain Scores on the Visual Analog Scale at 1 month
timeFrame: Change from Baseline Pain Scores at 1 month
measure: Change From Baseline in Pain Scores on the Visual Analog Scale at 3 months
timeFrame: Change from Baseline Pain Scores at 3 months
Secondary outcomes:
measure: Functional examination
timeFrame: Baseline, 1 month and 3 months
Other outcomes:
Locations:
Study officials:
References:
citation: Dogan M, Ozdemir Dogan D, Duger C, Ozdemir Kol I, Akpinar A, Mutaf B, Akar T. Effects of high-frequency bio-oxidative ozone therapy in temporomandibular disorder-related pain. Med Princ Pract. 2014;23(6):507-10. doi: 10.1159/000365355. Epub 2014 Sep 3.
citation: Daif ET. Role of intra-articular ozone gas injection in the management of internal derangement of the temporomandibular joint. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 Jun;113(6):e10-4. doi: 10.1016/j.tripleo.2011.08.006. Epub 2012 Feb 28.